Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a common drug slow kidney disease? new study investigates

NCT ID NCT07315139

Disease control Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether pentoxifylline, a drug used for blood flow issues, can reduce inflammation and slow kidney disease in non-diabetic patients. 42 adults with moderate chronic kidney disease took either standard therapy alone or standard therapy plus pentoxifylline for 6 months. Researchers measured changes in inflammatory markers to see if the drug helped.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pentoxifylline
What this could lead to
If it works, this could point toward a way to slow kidney disease progression in non-diabetic patients by reducing inflammation.
What could go wrong
This is a small, early-stage study with only 42 participants. Results may not apply to all kidney disease patients, and the drug may not show clear benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

42 people

The number who actually took part.

Started

Feb 2023

Finished

Aug 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ˃ 18 years old. * Both sexes. * Patients with chronic kidney disease (CKD) stages G3, G4. * Patients with proteinuria \< 1 g. Exclusion Criteria: * Patients who are terminally ill. * Patients with Diabetes mellitus. * Patients with proteinuria \> 1 g. * Patients with a history of hemodialysis. * Patients with active infection or hospitalized. * Patients with recent cerebral and /or retinal Hemorrhage. * Patients taking warfarin or theophylline-containing drugs. * women who are taking oral contraceptives, pregnant, or lactating * Patients with a history of adverse reactions to Pentoxifylline. * Patients with polycystic kidney disease. * Patients with obstructive uropathy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease Inflammatory markers Non-diabetic Pentoxifylline

Contacts and locations

Locations

  • Ain Shams University

    Cairo, 11591, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.